Post-earnings recap
Reported
Wed, Aug 7, 2013
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Arrowhead Pharmaceuticals reported a loss per share that was slightly worse than expected, leading to a 1.14% decline in stock price. The lack of revenue data and guidance may raise concerns among investors about the company's future performance. Management's cautious tone suggests they are navigating challenges but are focused on long-term objectives.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.23 | N/A | -4.55% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about market conditions impacting performance. They remain committed to their long-term goals.
Management noted challenges in the current market environment.
They emphasized a focus on long-term strategy despite short-term setbacks.